<DOC>
<DOCNO>EP-0620005</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of hydroxyethylstarch for the improvement of the microcirculation
</INVENTION-TITLE>
<CLASSIFICATIONS>C08B3100	A61K31715	A61P702	A61K31716	A61P700	A61K31715	A61P700	C08B3112	A61K31718	A61K3170	A61P708	A61K3170	C08B3110	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C08B	A61K	A61P	A61K	A61P	A61K	A61P	C08B	A61K	A61K	A61P	A61K	C08B	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C08B31	A61K31	A61P7	A61K31	A61P7	A61K31	A61P7	C08B31	A61K31	A61K31	A61P7	A61K31	C08B31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the use of a hydroxyethyl starch specification with a molecular weight Mw of 110,000 to 150,000, a degree of substitution MS of 0.38 to 0.5, a degree of substitution DS of 0.32 to 0.45 and a C2/C6 ratio of 8 to 20 for improving the microcirculation in cases of disturbance of peripheral arterial blood flow, especially in existent pAOD in Fontaine stage II. This hydroxyethyl starch specification can be used in suitable concentrations, e.g. as 6% by weight or 10% by weight solution, these solutions optionally containing conventional ancillary substances and additives.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
FRESENIUS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
FRESENIUS AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BEPPERLING FRANK DR
</INVENTOR-NAME>
<INVENTOR-NAME>
HENNING KLAUS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SOMMERMEYER KLAUS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WEIDLER BURGHARD PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
BEPPERLING, FRANK, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
HENNING, KLAUS, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SOMMERMEYER, KLAUS, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
WEIDLER, BURGHARD, PROF. DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a hydroxy ethyl starch with a molecular weight M
w
 of 110,000 to 150,000,
a substitution degree MS of 0.38 to 0.5, a substitution degree DS of 0.32 to 0.45

and a ratio of C
2
 : C
6
 of 8 to 20 in the manufacture of a medicament for improving
microcirculation in cases of peripheral arterial blood flow disturbance,
Use of the hydroxy ethyl starch according to claim 1 with a molecular weight M
w

of 110,000 to 150,000, a substitution degree MS of 0.38 to 0.45, a substitution
degree DS of 0.32 to 0.42 and a ratio of C
2
: C
6
 of 8 to 20.
Use of the hydroxy ethyl starch according to claim 1 or 2 in the manufacture of
a medicament for improving microcirculation in cases of Stage II (Fontaine)

peripheral arterial occlusion disease.
Use of the hydroxy ethyl starch according to claim 1, 2 or 3 in the manufacture of
a medicament in a 6% by weight or 10% by weight solution.
</CLAIMS>
</TEXT>
</DOC>
